000126435 001__ 126435
000126435 005__ 20240228140824.0
000126435 0247_ $$2doi$$a10.1097/TP.0000000000000471
000126435 0247_ $$2pmid$$apmid:25340610
000126435 0247_ $$2ISSN$$a0041-1337
000126435 0247_ $$2ISSN$$a1534-0608
000126435 0247_ $$2ISSN$$a1534-6080
000126435 0247_ $$2altmetric$$aaltmetric:2841167
000126435 037__ $$aDKFZ-2017-02464
000126435 041__ $$aeng
000126435 082__ $$a610
000126435 1001_ $$aDietrich, Sascha$$b0
000126435 245__ $$aPretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation.
000126435 260__ $$aHagerstown, Md.$$bLippincott Williams & Wilkins$$c2015
000126435 3367_ $$2DRIVER$$aarticle
000126435 3367_ $$2DataCite$$aOutput Types/Journal article
000126435 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523611883_20190
000126435 3367_ $$2BibTeX$$aARTICLE
000126435 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126435 3367_ $$00$$2EndNote$$aJournal Article
000126435 520__ $$aThe impact of nutritional status on outcome of allogeneic stem cell transplantation (alloSCT) is controversial. This study investigates the influence of pretransplant weight loss and serologic indicators of nutritional homeostasis on relapse and death of acute myeloid leukemia (AML) after alloSCT.Pretransplant weight loss along with serum levels of total serum protein (TSP), albumin, C-reactive protein, and leptin were collected retrospectively in a training cohort (n = 149) and correlated with clinical outcome. Metabolic risk groups were defined and tested in an independent validation cohort (n = 167).We identified pretransplant weight loss and TSP as strong independent predictors of relapse and death. Patients in the metabolic high-risk group (low TSP and weight loss) had an increased risk for relapse (P = 0.0002) and death (P = 0.002), but a similar risk for acute graft-versus-host disease. Weight loss coincided with reduced pretransplant serum leptin levels. The adverse influence of weight loss and high metabolic risk on relapse and overall survival could be confirmed in the validation cohort and similarly in patients with less than or more than 5% blasts before alloSCT. Multivariate analysis of both cohorts revealed a hazard ratio for relapse of 7.78 (2.59-23.36, P = 0.0003) in the metabolic high risk group.Altered nutritional homeostasis before alloSCT correlates with recurrence of AML after transplantation. Studies addressing pretransplant nutritional interventions to reduce AML relapse rates are warranted.
000126435 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000126435 588__ $$aDataset connected to CrossRef, PubMed,
000126435 650_7 $$2NLM Chemicals$$aBlood Proteins
000126435 650_7 $$2NLM Chemicals$$aLeptin
000126435 7001_ $$aRadujkovic, Aleksandar$$b1
000126435 7001_ $$aStölzel, Friedrich$$b2
000126435 7001_ $$aFalk, Christine S$$b3
000126435 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b4$$udkfz
000126435 7001_ $$aSchaich, Markus$$b5
000126435 7001_ $$aBornhäuser, Martin$$b6
000126435 7001_ $$aEhninger, Gerhard$$b7
000126435 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b8$$udkfz
000126435 7001_ $$aHegenbart, Ute$$b9
000126435 7001_ $$aHo, Anthony D$$b10
000126435 7001_ $$aDreger, Peter$$b11
000126435 7001_ $$aLuft, Thomas$$b12
000126435 773__ $$0PERI:(DE-600)2035395-9$$a10.1097/TP.0000000000000471$$gVol. 99, no. 5, p. 1065 - 1071$$n5$$p1065 - 1071$$tTransplantation$$v99$$x0041-1337$$y2015
000126435 909CO $$ooai:inrepo02.dkfz.de:126435$$pVDB
000126435 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126435 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126435 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000126435 9141_ $$y2015
000126435 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000126435 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126435 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSPLANTATION : 2015
000126435 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126435 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126435 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126435 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126435 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126435 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126435 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126435 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126435 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126435 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126435 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000126435 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x1
000126435 980__ $$ajournal
000126435 980__ $$aVDB
000126435 980__ $$aI:(DE-He78)C060-20160331
000126435 980__ $$aI:(DE-He78)G330-20160331
000126435 980__ $$aUNRESTRICTED